Editorial

2021 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles

Emmanuel J. Favaloro, PhD, FFSc (RCPA)¹

¹ Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, New South Wales, Australia

Semin Thromb Hemost 2021;47:467–476.

Welcome to the latest of our Eberhard F. Mammen award announcements. As noted in previous editorials (► **Table 1**), Thieme Medical and Scientific Publisher, the publisher of *Seminars in Thrombosis and Hemostasis* (STH), has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard F. Mammen (► **Fig. 1**) in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades. These awards began in 2009, under two categories, “Most Popular Article Awards” and “Young Investigator Awards.” Accordingly, 2021 represents in excess of 10 years of award presentations (► **Table 1**). Current details and conditions of the award can be summarized as follows:

- Most popular article awards: will be awarded to the authors of the most popular articles published in STH. The awards are determined by the Editor in Chief on the basis of user statistics from Thieme e-Journals from the preceding 2 years. Prefaces, Errata, Letters to the Editor, Editorials, Commentaries, and previous award-winning articles are excluded from further consideration of these awards which currently comprise two categories: one for “Open Access” articles and another for a “General Category.” There are two major cash prizes of U.S. \$1,000 for each category. In addition, winners of the “General Category” awards are granted “Open Access” status for these articles thereafter.
- Young investigator awards: the best presentation or meeting abstract by a young investigator as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen. Up to six cash prizes of U.S. \$1,000 in any year. There are some additional considerations and

conditions for the award, and awardees are expected to prepare a review or other paper related to the topic of their presentation (or as otherwise agreed) for publication in STH. In general, previous award winners are excluded from a second award to enable more individuals to be recognized. After nominations are received, the awardees are selected by a vote of the Senior Editors of STH. Any potential conflicts of interest are managed by first identifying these, and then excluding those with potential conflicts from voting. Finally, given the current COVID-19 (novel coronavirus disease 2019) pandemic, many international congresses have become virtual meetings, and accordingly, virtual meeting presentations can also be considered for the award.

Further details of the awards and the award winners are posted online (<https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077>), and previous award winner announcements are also available in print (► **Table 1**). This includes the recent announcement of the 2020 Young Investigator Awards.¹

It is, therefore, with great pleasure that we would like to announce the latest winners of the 2021 Eberhard F. Mammen awards for the most popular articles from STH for the period of 2019 to 2020 inclusive.

2021 “Most Popular” Article Awards

As mentioned, the “Most Popular” awards are given to the authors of the most popular articles published in STH as determined on the basis of user statistics from the publisher of this journal and covering the preceding 2-year period. Thus, the 2021 “Most Popular” awards are granted to the most popular papers from 2019 to 2020 inclusive. Previous

Address for correspondence
Emmanuel J. Favaloro, PhD, FFSc (RCPA), Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, New South Wales 2145, Australia
(e-mail: emmanuel.favaloro@health.nsw.gov.au).

Issue Theme Altered Fibrinolysis: Clinical Impact and Diagnostic Challenges; Guest Editors: Anne-Mette Hvas, MD, PhD, Julie Brogaard Larsen, MD, PhD, and Ton Lisman, MSc, PhD

© 2021. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.,
333 Seventh Avenue, 18th Floor,
New York, NY 10001, USA

DOI <https://doi.org/10.1055/s-0041-1726415>.
ISSN 0094-6176.

Table 1 Previous editorials related to Eberhard F. Mammen award announcements

1. Favaloro EJ. Welcome to a special issue of seminars in thrombosis and hemostasis—the closing issue for 2008. *Semin Thromb Hemost* 2008;34:693–696
2. Favaloro EJ. A tribute to Eberhard F. Mammen, M.D. (1930–2008). *Semin Thromb Hemost* 2008;34(8):703–707
3. Favaloro EJ. Welcome to the first issue of Seminars in Thrombosis and Hemostasis for 2009. *Semin Thromb Hemost* 2009;35:1–2
4. Favaloro EJ. Winners of the inaugural Eberhard F. Mammen award for most popular article. *Semin Thromb Hemost* 2009;35:587–590
5. Favaloro EJ. Editorial. 2009 Eberhard F. Mammen young investigator award winners. *Semin Thromb Hemost* 2010;36:469–470
6. Favaloro EJ. Winners of the 2010 Eberhard F. Mammen award for most popular article during 2008–2009. *Semin Thromb Hemost* 2010;36(7):685–692
7. Favaloro EJ. 2011 Eberhard F. Mammen award announcements. *Semin Thromb Hemost* 2011;37(5):431–439
8. Favaloro EJ. 2012 Eberhard F. Mammen award announcements. *Semin Thromb Hemost* 2012;38:425–432
9. Favaloro EJ. Eberhard F. Mammen award announcements. *Semin Thromb Hemost* 2013;39:567–574
10. Favaloro EJ. 2014 Eberhard F. Mammen award announcements: part I—most popular articles. *Semin Thromb Hemost* 2014;40(4):407–412
11. Favaloro EJ. 2014 Eberhard F. Mammen award announcements: part II—Young Investigator Awards. *Semin Thromb Hemost* 2014;40(7):718–723
12. Favaloro EJ. 2015 Eberhard F. Mammen award announcements: part I—most popular articles. *Semin Thromb Hemost* 2015;41(7):673–679
13. Favaloro EJ. 2015 Eberhard F. Mammen award announcements: part II—young investigator awards. *Semin Thromb Hemost* 2015;41(8):809–815
14. Favaloro EJ. 2016 Eberhard F. Mammen award announcements: part I—most popular articles. *Semin Thromb Hemost* 2016;42(4):325–330
15. Favaloro EJ. 2016 Eberhard F. Mammen Award announcements: part II—young investigator awards. *Semin Thromb Hemost* 2017;43(3):235–241
16. Favaloro EJ. 2017 Eberhard F. Mammen award announcements: part I—most popular articles. *Semin Thromb Hemost* 2017;43(4):357–363
17. Favaloro EJ. 2017 Eberhard F. Mammen award announcements: part II—young investigator awards. *Semin Thromb Hemost* 2018;44(2):81–88
18. Favaloro EJ. 2018 Eberhard F. Mammen award announcements: part I—most popular articles. *Semin Thromb Hemost* 2018;44(3):185–192
19. Favaloro EJ. 2018 Eberhard F. Mammen award announcements: part II—young investigator awards. *Semin Thromb Hemost* 2019;45(2):123–129
20. Favaloro EJ. 2019 Eberhard F. Mammen award announcements: part I—most popular articles. *Semin Thromb Hemost* 2019;45(3):215–224
21. Favaloro EJ. 2019 Eberhard F. Mammen award announcements: part II—young investigator awards. *Semin Thromb Hemost* 2020;46(2):105–113
22. Favaloro EJ. 2020 Eberhard F. Mammen award announcements: part I—most popular articles. *Semin Thromb Hemost* 2020;46(4):383–392
23. Favaloro EJ. 2020 Eberhard F. Mammen award announcements: part II—young investigator awards. *Semin Thromb Hemost* 2021;46(3): 229–237

Eberhard F. Mammen award winning articles are listed in ► **Table 2**. These articles are currently freely available under an “Open Access” status and no longer qualify for future awards, although many will continue to appear in the most popular download statistics provided by the publisher. Indeed, as expected, many of the previous award-winning

Fig. 1 Eberhard F. Mammen (1930–2008).

articles appeared in the top 100 list (2019–2020 inclusive), with most also ranking highly, and thus still proving popular with our readership.

There is also an increasingly recognized trend to publish articles under an open-access model, and these, therefore, have an “inequitable advantage” over other “non-open access” articles in terms of potential for downloads or perceived popularity due to their open accessibility. Accordingly, the publisher of STH established a separate category of the “Most Popular” award for “Open Access” papers to supplement the original and now alternate “General Category.” Thus, the most popular papers are now listed in separate tables. ► **Table 3** lists the top 20 downloaded “Open Access” articles from STH (2019 and 2020 inclusive), as eligible for the “Open Access” award.^{2–21} ► **Table 4** lists the top 25 downloaded non-open access articles from STH (2019 and 2020 inclusive), as otherwise eligible for the “General Category” award.^{22–46}

Table 2 Previous most popular award-winning papers

Year	Awarded for	Position in 2021 top 100 list
2009	Jurk K, Kehrel BE. Platelets: physiology and biochemistry. <i>Semin Thromb Hemost</i> 2005;31(4):381–392	15
2009	Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. <i>Semin Thromb Hemost</i> 2006;32(8):803–809	NL
2010	Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. <i>Semin Thromb Hemost</i> 2008;34(1):39–57	NL
2010	Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. <i>Semin Thromb Hemost</i> 2008;34(1):86–96	NL
2010	Fareed J, Hoppensteadt DA, Fareed D, et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. <i>Semin Thromb Hemost</i> 2008;34(1):58–73	NL
2011	Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. <i>Semin Thromb Hemost</i> 2009;35(5):515–524	NL
2011	Mariani G, Bernardi F. Factor VII deficiency. <i>Semin Thromb Hemost</i> 2009;35(4):400–406	13
2012	Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox”. <i>Semin Thromb Hemost</i> 2010;36(1):59–70	11
2012	Rak J. Microparticles in cancer. <i>Semin Thromb Hemost</i> 2010;36(8):888–906	45
2013	Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. <i>Semin Thromb Hemost</i> 2011;37(3):280–297	68
2013	Tufano A, Guida A, Di Minno MN, Prisco D, Cerbone AM, Di Minno G. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. <i>Semin Thromb Hemost</i> 2011;37(3):267–274	28
2014	Salmela B, Jouts-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. <i>Semin Thromb Hemost</i> 2012;38(1):23–30	NL
2014	Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. <i>Semin Thromb Hemost</i> 2012;38(1):47–54	75
2014	Kenet G, Aronis S, Berkun Y, et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. <i>Semin Thromb Hemost</i> 2011;37(7):802–809	22
2015	Tapson VF. Thrombolytic therapy for acute pulmonary embolism. <i>Semin Thromb Hemost</i> 2013;39(4):452–458	47
2015	George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. <i>Semin Thromb Hemost</i> 2013;39(2):153–160	42
2015 ^a	Hylek EM. Anticoagulation therapy for atrial fibrillation. <i>Semin Thromb Hemost</i> 2013;39(2):147–152	NL
2015 ^a	Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. <i>Semin Thromb Hemost</i> 2013;39(2):117–126	NL
2016	de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. <i>Semin Thromb Hemost</i> 2013;39(6):585–595	9
2016	Sethi S, Fervenza FC. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). <i>Semin Thromb Hemost</i> 2014;40(4):416–421	49
2016 ^a	Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. <i>Semin Thromb Hemost</i> 2012;38(7):673–682	52
2016 ^a	Lippi G, Favaloro EJ, Meschi T, Mattiuzzi C, Borghi L, Cervellini G. E-cigarettes and cardiovascular risk: beyond science and mysticism. <i>Semin Thromb Hemost</i> 2014;40(1):60–65	6

(Continued)

Table 2 (Continued)

Year	Awarded for	Position in 2021 top 100 list
2017	Boonyawat K, Crowther MA. Venous thromboembolism prophylaxis in critically ill patients. <i>Semin Thromb Hemost</i> 2015;41(1):68–74	19
2017	Levi M, Poll TV. Coagulation in patients with severe sepsis. <i>Semin Thromb Hemost</i> 2015;41(1):9–15	65
2017 ^a	Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. <i>Semin Thromb Hemost</i> 2014;40(2):163–171	7
2017 ^a	Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. <i>Semin Thromb Hemost</i> 2015;41(1):49–60	55
2017 ^b	Favaloro EJ, Lippi G. Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors. <i>Semin Thromb Hemost</i> 2015;41(2):208–227	53
2018	Gremmel T, Frelinger AL III, Michelson AD. Platelet physiology. <i>Semin Thromb Hemost</i> 2016;42(3):191–204	1
2018	Mallett SV. Clinical utility of viscoelastic tests of coagulation (TEG/ROTEM) in patients with liver disease and during liver transplantation. <i>Semin Thromb Hemost</i> 2015;41(5):527–537	35
2018 ^a	Cuker A, Prak ET, Cines DB. Can immune thrombocytopenia be cured with medical therapy? <i>Semin Thromb Hemost</i> 2015;41(4):395–404	59
2018 ^a	Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. <i>Semin Thromb Hemost</i> 2014;40(1):106–114	77
2019	Klil-Drori AJ, Tagalakakis V. Direct oral anticoagulants in end-stage renal disease. <i>Semin Thromb Hemost</i> 2018;44(4):353–363	16
2019	Kitchen S, Tiefenbacher S, Gosselin R. Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies. <i>Semin Thromb Hemost</i> 2017;43(3):331–337	37
2019 ^a	Kell DB, Pretorius E. To what extent are the terminal stages of sepsis, septic shock, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome actually driven by a prion/amyloid form of fibrin? <i>Semin Thromb Hemost</i> 2018;44(3):224–238	27
2019 ^a	Chighizola CB, Raimondo MG, Meroni PL. Management of thrombotic antiphospholipid syndrome. <i>Semin Thromb Hemost</i> 2018;44(5):419–426	41
2020	Kumar KR, Cowley MJ, Davis RL. Next-generation sequencing and emerging technologies. <i>Semin Thromb Hemost</i> 2019;45(7):661–673	5
2020	Russo V, Attena E, Mazzone C, et al. Nonvitamin K antagonist oral anticoagulants use in patients with atrial fibrillation and bioprosthetic heart valves/prior surgical valve repair: a multicenter clinical practice experience. <i>Semin Thromb Hemost</i> 2018;44(4):364–369	60
2020 ^a	Lippi G, Favaloro EJ, Sanchis-Gomar F. Sudden cardiac and noncardiac death in sports: epidemiology, causes, pathogenesis, and prevention. <i>Semin Thromb Hemost</i> 2018;44(8):780–786	24
2020 ^a	Schreiber K, Breen K, Cohen H, et al. Hydroxychloroquine to improve pregnancy outcome in women with Antiphospholipid Antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. <i>Semin Thromb Hemost</i> 2017;43(6):562–571	23

Abbreviation: NL, not listed in top 100 listing.

^aNew open access category created in 2015.

^bThis paper qualified as a “Most Popular” award winner based on objective publisher provided download data; however, as this paper was written by the journal Editor in Chief, there was an obvious conflict of interest, and the award was officially declined. This paper is listed here merely as a statement of record.

Table 3 Most popular papers—"Open Access" category^a

Rank	Publication
1	Gosselin RC, Adcock D, Dorgalaleh A, et al. International Council for Standardization in Haematology recommendations for hemostasis critical values, tests, and reporting. <i>Semin Thromb Hemost</i> 2020;46(4):398–409
2	Gosselin RC, Marlar RA. Preanalytical variables in coagulation testing: setting the stage for accurate results. <i>Semin Thromb Hemost</i> 2019;45(5):433–448
3	Page MJ, Pretorius E. A champion of host defense: a generic large-scale cause for platelet dysfunction and depletion in infection. <i>Semin Thromb Hemost</i> 2020;46(3):302–319
4	Al-Samkari H, Kuter DJ. Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment. <i>Semin Thromb Hemost</i> 2020;46(3):275–288
5	Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. <i>Semin Thromb Hemost</i> 2020;46(7):763–771
6	Harenberg J, Schreiner R, Hetjens S, Weiss C. Detecting anti-IIa and anti-Xa direct oral anticoagulant (DOAC) agents in urine using a DOAC dipstick. <i>Semin Thromb Hemost</i> 2019;45(3):275–284
7	Althaus K, Greinacher A. MYH9-related platelet disorders. <i>Semin Thromb Hemost</i> 2009;35(2):189–203
8	Lippi G, Danese E, Favaloro EJ. Harms and benefits of using aspirin for primary prevention of cardiovascular disease: a narrative overview. <i>Semin Thromb Hemost</i> 2019;45(2):157–163
9	Lippi G, Salvagno GL, Gelati M, Poli G, Giavarina D, Favaloro EJ. Analytical assessment of the new Roche Cobas t 711 fully automated coagulation analyzer. <i>Semin Thromb Hemost</i> 2019;45(3):308–314
10	Lindholm PF, Ramsey G, Kwaan HC. Passive immunity for coronavirus disease 2019: a commentary on therapeutic aspects including convalescent plasma. <i>Semin Thromb Hemost</i> 2020;46(7):796–803
11	van der Vorm LN, Huskens D, Kicken CH, et al. Effects of repeated bouts of exercise on the hemostatic system. <i>Semin Thromb Hemost</i> 2018;44(8):710–722
12	Zadow EK, Wundersitz DWT, Hughes DL, et al. Coronavirus (COVID-19), coagulation, and exercise: interactions that may influence health outcomes. <i>Semin Thromb Hemost</i> 2020;46(7):807–814
13	Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. <i>Semin Thromb Hemost</i> 2014;40(3):277–283
14	Raskob GE, Angchaisuksiri P, Blanco AN, et al; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. <i>Semin Thromb Hemost</i> 2014;40(7):724–735
15	Favaloro EJ. Clinical utility of the PFA-100. <i>Semin Thromb Hemost</i> 2008;34(8):709–733
16	Stufano F, Boscarino M, Bucciarelli P, et al. Evaluation of the utility of von Willebrand factor propeptide in the differential diagnosis of von Willebrand disease and acquired von Willebrand syndrome. <i>Semin Thromb Hemost</i> 2019;45(1):36–42
17	Favaloro EJ, Pasalic L, Curnow J. Type 2M and Type 2A von Willebrand disease: similar but different. <i>Semin Thromb Hemost</i> 2016;42(5):483–497
18	Lim MS, Indran T, Cummins A, et al. Utility of a nurse-led pathway for patients with acute venous thromboembolism discharged on rivaroxaban: a prospective cohort study. <i>Semin Thromb Hemost</i> 2019;45(2):187–195
19	Mannucci PM, Mancuso ME, Santagostino E, Franchini M. Innovative pharmacological therapies for the hemophilias not based on deficient factor replacement. <i>Semin Thromb Hemost</i> 2016;42(5):526–532
20	Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. <i>Semin Thromb Hemost</i> 2008;34(8):772–778

^a2019–2020 inclusive. Ranking is according to download data provided by journal publisher, and excludes non-qualifying material (e.g., Prefaces, Errata, Letter to the Editor, Editorials, Commentaries, and previous award-winning articles).

Accordingly, the 2021 Eberhard F. Mammen award winners for most popular article (2019/2020 inclusive) are mentioned below:

Open Access Category

1. Gosselin RC, Adcock D, Dorgalaleh A, Favaloro EJ, Lippi G, Pego JM, Regan I, Siguret V. International Council for Standardization in Haematology Recommendations for hemostasis critical values, tests, and reporting. *Semin Thromb Hemost* 2020;46(4):398–409.²

2. Gosselin RC, Marlar RA. Preanalytical Variables in Coagulation Testing: Setting the Stage for Accurate Results. *Semin Thromb Hemost* 2019;45(5):433–448.³

General Category

1. Iba T, Levi M, Levy JH. Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. *Semin Thromb Hemost* 2020;46(1):89–95.²²
2. Thomas J, Kostousov V, Teruya J. Bleeding and Thrombotic Complications in the Use of Extracorporeal Membrane Oxygenation. *Semin Thromb Hemost* 2018;44(1):20–29.²³

Table 4 Most popular papers—"General" category^a

Rank	Publication
1	Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. <i>Semin Thromb Hemost</i> 2020;46(1):89–95
2	Thomas J, Kostousov V, Teruya J. Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation. <i>Semin Thromb Hemost</i> 2018;44(1):20–29
3	Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. <i>Semin Thromb Hemost</i> 2019;45(1):86–93
4	Scharf RE. Drugs that affect platelet function. <i>Semin Thromb Hemost</i> 2012;38(8):865–883
5	Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. <i>Semin Thromb Hemost</i> 2004;30(5):579–589
6	MacLachlan KH, Stevens HP, Tran HA, Chunal SD. Weight-based enoxaparin for venous thromboembolism in obesity gives similar anti-Xa levels to patients <100 kg, with no increase in major bleeding. <i>Semin Thromb Hemost</i> 2019;45(1):94–99
7	Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. <i>Semin Thromb Hemost</i> 2003;29(5):435–450
8	Franchini M, Mannucci PM. The history of hemophilia. <i>Semin Thromb Hemost</i> 2014;40(5):571–576
9	Favaloro EJ, Kershaw G, Mohammed S, Lippi G. How to optimize activated partial thromboplastin time (APTT) testing: solutions to establishing and verifying normal reference intervals and assessing APTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting factors. <i>Semin Thromb Hemost</i> 2019;45(1):22–35
10	Marlar RA, Clement B, Gausman J. Activated partial thromboplastin time monitoring of unfractionated heparin therapy: issues and recommendations. <i>Semin Thromb Hemost</i> 2017;43(3):253–260
11	Bolliger D, Tanaka KA. Point-of-care coagulation testing in cardiac surgery. <i>Semin Thromb Hemost</i> 2017;43(4):386–396
12	Bikdeli B, Abou Ziki MD, Lip GYH. Pulmonary embolism and atrial fibrillation: two sides of the same coin? A systematic review. <i>Semin Thromb Hemost</i> 2017;43(8):849–863
13	Mahajan A, Brunson A, White R, Wun T. The epidemiology of cancer-associated venous thromboembolism: an update. <i>Semin Thromb Hemost</i> 2019;45(4):321–325
14	Van Cott EM, Roberts AJ, Dager WE. Laboratory monitoring of parenteral direct thrombin inhibitors. <i>Semin Thromb Hemost</i> 2017;43(3):270–276
15	Davie EW, Kulman JD. An overview of the structure and function of thrombin. <i>Semin Thromb Hemost</i> 2006;32(suppl 1):3–15
16	Reynen E, James P. Von Willebrand disease and pregnancy: a review of evidence and expert opinion. <i>Semin Thromb Hemost</i> 2016;42(7):717–723
17	McEwen BJ. The influence of herbal medicine on platelet function and coagulation: a narrative review. <i>Semin Thromb Hemost</i> 2015;41(3):300–314
18	Thachil J. The elusive diagnosis of disseminated intravascular coagulation: does a diagnosis of DIC exist anymore? <i>Semin Thromb Hemost</i> 2019;45(1):100–107
19	Lippi G, Plebani M, Favaloro EJ. Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. <i>Semin Thromb Hemost</i> 2013;39(3):258–266
20	Arachchillage DRJ, Makris M. Inherited thrombophilia and pregnancy complications: should we test? <i>Semin Thromb Hemost</i> 2019;45(1):50–60
21	Lippi G, Gosselin R, Favaloro EJ. Current and emerging direct oral anticoagulants: state-of-the-art. <i>Semin Thromb Hemost</i> 2019;45(5):490–501
22	Molhoek JE, de Groot PG, Urbanus RT. The lupus anticoagulant paradox. <i>Semin Thromb Hemost</i> 2018;44(5):445–452
23	Anker-Møller T, Trolborg A, Sunde N, Hvas AM. Evidence for the use of tranexamic acid in subarachnoid and subdural hemorrhage: a systematic review. <i>Semin Thromb Hemost</i> 2017;43(7):750–758
24	Arachchillage DR, Laffan M. Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms. <i>Semin Thromb Hemost</i> 2019;45(6):604–611
25	Grandone E, Ostuni A, Tiscia GL, Marongiu F, Barcellona D. Management of patients taking oral anticoagulants who need urgent surgery for hip fracture. <i>Semin Thromb Hemost</i> 2019;45(2):164–170

^a2019–2020 inclusive. Ranking is according to download data provided by journal publisher, and excludes non-qualifying material (e.g., Prefaces, Errata, Letter to the Editor, Editorials, Commentaries, and previous award-winning articles).

Table 5 COVID-19-related papers, also very popular^a

Publication	Position in 2021 top 100 list
Favaloro EJ, Lippi G. Recommendations for minimal laboratory testing panels in patients with COVID-19: potential for prognostic monitoring. <i>Semin Thromb Hemost</i> 2020;46(3):379–382	3
Thachil J, Srivastava A. SARS-2 coronavirus-associated hemostatic lung abnormality in COVID-19: is it pulmonary thrombosis or pulmonary embolism? <i>Semin Thromb Hemost</i> 2020;46(7):777–780	4
Schulman S. Coronavirus disease 2019, prothrombotic factors, and venous thromboembolism. <i>Semin Thromb Hemost</i> 2020;46(7):772–776	10
Kwaan HC. Coronavirus disease 2019: the role of the fibrinolytic system from transmission to organ injury and sequelae. <i>Semin Thromb Hemost</i> 2020;46(7):841–844	17
Larsen JB, Pasalic L, Hvas AM. Platelets in coronavirus disease 2019. <i>Semin Thromb Hemost</i> 2020;46(7):823–825	21
de Maat S, de Mast Q, Danser AHJ, van de Veerdonk FL, Maas C. Impaired breakdown of bradykinin and its metabolites as a possible cause for pulmonary edema in COVID-19 infection. <i>Semin Thromb Hemost</i> 2020;46(7):835–837	26
Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. <i>Semin Thromb Hemost</i> 2020;46(7):763–771	29
Levi M, Thachil J. Coronavirus disease 2019 coagulopathy: disseminated intravascular coagulation and thrombotic microangiopathy-either, neither, or both. <i>Semin Thromb Hemost</i> 2020;46(7):781–784	30
Coppola A, Tagliaferri A, Rivolta GF, Quintavalle G, Franchini M. Confronting COVID-19: issues in hemophilia and congenital bleeding disorders. <i>Semin Thromb Hemost</i> 2020;46(7):819–822	46
Lindholm PF, Ramsey G, Kwaan HC. Passive immunity for coronavirus disease 2019: a commentary on therapeutic aspects including convalescent plasma. <i>Semin Thromb Hemost</i> 2020;46(7):796–803	50
Hashemi A, Madhavan MV, Bikdeli B. Pharmacotherapy for prevention and management of thrombosis in COVID-19. <i>Semin Thromb Hemost</i> 2020;46(7):789–795	79
Dorgalaleh A, Dabbagh A, Tabibian S, et al. Patients with congenital bleeding disorders appear to be less severely affected by SARS-CoV-2: is inherited hypocoagulability overcoming acquired hypercoagulability of coronavirus disease 2019 (COVID-19)? <i>Semin Thromb Hemost</i> 2020;46(7):853–855	94

Abbreviation: COVID-19, novel coronavirus disease 2019.

^a2019–2020 inclusive. Ranking is according to download data provided by journal publisher, and includes nonqualifying material (e.g., Letters to the Editor and Commentaries) for “Most Popular” awards. All COVID-19 related material provided as free to download by Thieme.

I will note that although I was a coauthor of one of the award-winning articles, my relative contribution was minor in comparison to the lead author, and I will of course decline to receive any of the award prize.

As always, and irrespective of any personal involvement in the writing of papers that are published in this journal, I always get considerable satisfaction in announcing these awards. This year also saw that one lead author, Robert C. Gosselin, wins two of the top prizes for separate papers published in separate years.^{2,3} Indeed, one of these papers was published in 2020,² and so is especially deserving, given the later publication of the 2-year, 2019 and 2020, capture period. This paper was prepared on behalf of the International Council for Standardization in Haematology (ICSH).⁴⁷ It was only at e-First publication stage at the time of writing the previous editorial related to the 2020 Eberhard F. Mammen “Most Popular” articles award announcements.⁴⁸ Nevertheless, it rated high on the 2020 listing and I predicted it to be very difficult to beat for the 2021 “Most Popular” award.⁴⁸ The 2021 winner proves my prediction to be correct, despite some later “competition” by popular COVID-19-related papers.

As always, the listing also identified some older yet popular papers in ► **Tables 3** and **4** and thus indicates some topics of current interest that STH will likely revisit in forthcoming years.

It is certainly always of interest to see what captures the attention of the STH readership. Some topics and issues of STH, in particular, seem to catch a larger readership. This was certainly true of COVID-19 papers. STH published an issue on COVID-19 in 2020⁴⁹ and plans at least one issue in 2021. Indeed, most of the papers that appeared in the 2020 COVID-19 issue also appeared in the top 100 download list, as listed in ► **Table 5**. Notably, most of these papers were Commentaries, and thus do not qualify for the award. However, there were a couple of reviews included in the issue, and these would likely be qualifiers for the 2022 “Most Popular” award.

The other top-ranking issues of STH this round, from the aspect of having three or more papers appearing in the top 100 download list, and published in the past 5 years were: “Acquired Platelet Dysfunction-Laboratory and Clinical Implications.” (2020),⁵⁰ “Innovations in Thrombosis and Hemostasis: A Glimpse Towards the Future of Diagnostic

Fig. 2 Robert C. Gosselin.

Analyzers.” (2019),⁵¹ “Recent Advances in Thrombosis and Hemostasis-Part IV.” (2019),⁵² “Editorial Compilation VI” (2019),⁵³ “Hemostasis in Exercise and the Athlete.” (2018),⁵⁴ and “Editorial Compilation V” (2017).⁵⁵

It can be noted here that the latest “nonthemed” issues (into which primarily go the best of unsolicited manuscripts) were well represented as “leading” issues, according to this marker of “popularity.” This would help to vindicate the decision to progress such issues approximately every 8 months.

All authors of the award-winning articles were thrilled to hear that their papers had won an Eberhard F. Mammen “Most Popular” award, and provided their own personal responses to the news.

From Robert C. Gosselin (►**Fig. 2**), “on behalf of my coauthors, it is truly an honor to be bestowed two Eberhard F. Mammen “Most Popular” article awards. Dr Mammen had a particular fondness for teaching, especially laboratory technologists, which has inspired so many including myself to reach out and share our experiences. It is my belief that a significant feature for these awards is the acknowledgement that our colleagues yearn for these manuscripts that provide technical guidance, and thus we are immensely grateful to STH for their willingness to provide such a platform for these articles related to laboratory practice. I would also like to thank Siemens Healthcare Diagnostics for providing Dr. Marlar (►**Fig. 3**) and myself the inspiration to write the preanalytical variable manuscript, as well as the ICSH for providing support for the coagulation critical value manuscript.”

Richard A. Marlar (►**Fig. 4**) added, “I wish to thank the editors and staff of STH for awarding Bob Gosselin and myself the honor of an Eberhard F. Mammen “Most Popular” article award for our article on preanalytical variables. Dr. Mammen truly was gifted for teaching and mentoring. I knew him throughout my career from his classroom teaching while in graduate school at the start of my career to mentoring and helping me set my direction into coagulation laboratory science. Finally, he continued to advise and mentor throughout my career on many different topics. It is truly an honor for me to have worked and interacted with him and his family. Thanks must be also extended to Siemens Healthcare Diagnostics for providing the opportunity to write a review

Fig. 3 Richard A. Marlar.

manuscript on preanalytical variables in coagulation. And for the willingness of the editors of this journal to review and then accept our manuscript. It is gratifying to know that our work was truly needed and hopefully has helped make coagulation laboratories better.”

It was very pleasing to see (open disclosure here: my friend and sometimes collaborator) Robert C. Gosselin win awards for these two reviews.^{2,3} I recall the development of both these manuscripts, both appearing in separate issues in which I and another friend and sometimes collaborator, Prof. Giuseppe Lippi, guest edited.^{56,57} Also of interest, Robert C. Gosselin was coauthor of a 2019 “Most Popular” award winning paper.^{58,59} Also of interest, especially as a connection to Dr. Mammen, is that Robert C. Gosselin was a coauthor on one of Dr. Mammen’s publications appearing in STH in 1998.⁶⁰

From Toshiaki Iba (►**Fig. 4**), speaking on behalf of all authors (also appearing in ►**Fig. 4**), “we are greatly honored to have received one of the Eberhard F. Mammen STH 2021 “Most Popular” article awards. Upon receiving the award, we must confess that the concept of disseminated intravascular coagulation (DIC) has not yet been integrated between the scientists and countries *per se*. DIC has perhaps become diffuse intercerebral confusion or disseminated intercontinental chaos. My wonderful colleagues Profs. Jerrold H. Levy and Marcel Levi and I have been worked on unifying the concept of sepsis-associated DIC and released the diagnostic criteria for sepsis-induced coagulopathy (SIC) in 2017. Since then, we are continuously working on expanding the “two-step approach (SIC to DIC)” to manage DIC in sepsis. Our future target is establishing an effective strategy for DIC. We also wish to clarify the difference and similarities between SIC and COVID-19-associated coagulopathy. We are extremely happy that we could introduce this process in this prestigious journal.”

From Jun Teruya (►**Fig. 5**), speaking also on behalf of his coauthors (also appearing in ►**Fig. 5**): “we were surprised, thrilled, and grateful to hear that our paper had won one of the 2021 Eberhard F. Mammen “Most Popular” awards for the “General Category.” We are pleased to know that our article entitled “Bleeding and Thrombotic Complications in the Use of Extracorporeal Membrane Oxygenation (ECMO)” was widely read by people who presumably manage patients on ECMO on a daily basis. Even with the advancement of recent technology, we still struggle with bleeding and

Fig. 4 From left: Jerrold H. Levy, Toshiaki Iba, Marcel Levi.

Fig. 5 From left: James Thomas, Vadim Kostousov, extracorporeal membrane oxygenation (ECMO) machine, Jun Teruya.

thrombosis during ECMO. We hope that our article was helpful to guide management of patients on ECMO. On a personal note, I was fortunate to attend Dr. Mammen's talk when he came to Tokyo, Japan, in the late 1980's. I was a resident at that time, but his talk convinced me to specialize in hemostasis as my career."

Also interesting is that several papers on the top listings were coauthored by previous Young Investigator Award winners, for example, the paper by Laridan et al,²⁴ which just missed out on a "Most Popular" award, being third on the list in ▶ **Table 4**. Elodie Laridan was a 2017 "Young Investigator" award winner,⁶¹ and this paper represents the contribution submitted as part of the award. This also further helps to validate the "Young Investigator" awards process itself.

Also, perhaps notable is that several of the papers listed on the most popular tables are original studies,^{10,17,19,27} or what I call "hybrid papers" (representing some original data and a review of the literature).¹² Given the current restrictive Publication Policy for original studies published in STH,⁶² I find it interesting that four original studies published in 2019 appeared on the top 100 listing. In brief, STH publishes a maximum of 10 to 12 original studies per year, and these also require additional oversight with external to STH-board peer review. Nonetheless, that 4 of 11 original studies published in 2019 appeared in the top 100 seems to validate the Editorial Board's decision to continue to publish selected unsolicited

submissions of original studies. Of note, an original study also won one of the 2020 "Most Popular" awards.^{48,63}

I would, as always, like to thank not only all of the authors listed in ▶ **Tables 2–5**, but also all the other contributing authors who didn't manage to make these listings, as well as all the many other guest editors of issues recently published in STH. I likewise look forward to seeing future listings, always a great pleasure and sometimes a surprise.

Conflict of Interest

None declared.

References

- 1 Favaloro EJ. 2020 Eberhard F. Mammen award announcements: part II—young investigator awards. *Semin Thromb Hemost* 2021; 47(03):229–237
- 2 Gosselin RC, Adcock D, Dorgalaleh A, et al. International Council for Standardization in Haematology recommendations for hemostasis critical values, tests, and reporting. *Semin Thromb Hemost* 2020;46(04):398–409
- 3 Gosselin RC, Marlar RA. Preanalytical variables in coagulation testing: setting the stage for accurate results. *Semin Thromb Hemost* 2019;45(05):433–448
- 4 Page MJ, Pretorius E. A champion of host defense: a generic large-scale cause for platelet dysfunction and depletion in infection. *Semin Thromb Hemost* 2020;46(03):302–319
- 5 Al-Samkari H, Kuter DJ. Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment. *Semin Thromb Hemost* 2020;46(03):275–288
- 6 Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. *Semin Thromb Hemost* 2020;46(07):763–771
- 7 Harenberg J, Schreiner R, Hetjens S, Weiss C. Detecting anti-IIa and anti-Xa direct oral anticoagulant (DOAC) agents in urine using a DOAC dipstick. *Semin Thromb Hemost* 2019;45(03):275–284
- 8 Althaus K, Greinacher A. MYH9-related platelet disorders. *Semin Thromb Hemost* 2009;35(02):189–203
- 9 Lippi G, Danese E, Favaloro EJ. Harms and benefits of using aspirin for primary prevention of cardiovascular disease: a narrative overview. *Semin Thromb Hemost* 2019;45(02):157–163
- 10 Lippi G, Salvagno GL, Gelati M, Poli G, Giavarina D, Favaloro EJ. Analytical assessment of the new Roche Cobas t 711 fully automated coagulation analyzer. *Semin Thromb Hemost* 2019;45(03):308–314
- 11 Lindholm PF, Ramsey G, Kwaan HC. Passive immunity for coronavirus disease 2019: a commentary on therapeutic aspects including convalescent plasma. *Semin Thromb Hemost* 2020;46(07):796–803
- 12 van der Vorm LN, Huskens D, Kicken CH, et al. Effects of repeated bouts of exercise on the hemostatic system. *Semin Thromb Hemost* 2018;44(08):710–722
- 13 Zadow EK, Wundersitz DWT, Hughes DL, et al. Coronavirus (COVID-19), coagulation, and exercise: interactions that may influence health outcomes. *Semin Thromb Hemost* 2020;46(07):807–814
- 14 Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-associated thrombosis. *Semin Thromb Hemost* 2014;40(03):277–283
- 15 Raskob GE, Angchaisuksiri P, Blanco AN, et al; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. *Semin Thromb Hemost* 2014;40(07):724–735
- 16 Favaloro EJ. Clinical utility of the PFA-100. *Semin Thromb Hemost* 2008;34(08):709–733
- 17 Stufano F, Boscarino M, Bucciarelli P, et al. Evaluation of the utility of von Willebrand factor propeptide in the differential diagnosis

- of von Willebrand disease and acquired von Willebrand syndrome. *Semin Thromb Hemost* 2019;45(01):36–42
- 18 Favaloro EJ, Pasalic L, Curnow J. Type 2M and Type 2A von Willebrand disease: similar but different. *Semin Thromb Hemost* 2016;42(05):483–497
 - 19 Lim MS, Indran T, Cummins A, et al. Utility of a nurse-led pathway for patients with acute venous thromboembolism discharged on rivaroxaban: a prospective cohort study. *Semin Thromb Hemost* 2019;45(02):187–195
 - 20 Mannucci PM, Mancuso ME, Santagostino E, Franchini M. Innovative pharmacological therapies for the hemophilias not based on deficient factor replacement. *Semin Thromb Hemost* 2016;42(05):526–532
 - 21 Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. *Semin Thromb Hemost* 2008;34(08):772–778
 - 22 Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. *Semin Thromb Hemost* 2020;46(01):89–95
 - 23 Thomas J, Kostousov V, Teruya J. Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation. *Semin Thromb Hemost* 2018;44(01):20–29
 - 24 Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. *Semin Thromb Hemost* 2019;45(01):86–93
 - 25 Scharf RE. Drugs that affect platelet function. *Semin Thromb Hemost* 2012;38(08):865–883
 - 26 Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. *Semin Thromb Hemost* 2004;30(05):579–589
 - 27 MacLachlan KH, Stevens HP, Tran HA, Chunilal SD. Weight-based enoxaparin for venous thromboembolism in obesity gives similar anti-Xa levels to patients <100 kg, with no increase in major bleeding. *Semin Thromb Hemost* 2019;45(01):94–99
 - 28 Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. *Semin Thromb Hemost* 2003;29(05):435–450
 - 29 Franchini M, Mannucci PM. The history of hemophilia. *Semin Thromb Hemost* 2014;40(05):571–576
 - 30 Favaloro EJ, Kershaw G, Mohammed S, Lippi G. How to optimize activated partial thromboplastin time (APTT) testing: solutions to establishing and verifying normal reference intervals and assessing APTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting factors. *Semin Thromb Hemost* 2019;45(01):22–35
 - 31 Marlar RA, Clement B, Gausman J. Activated partial thromboplastin time monitoring of unfractionated heparin therapy: issues and recommendations. *Semin Thromb Hemost* 2017;43(03):253–260
 - 32 Bolliger D, Tanaka KA. Point-of-care coagulation testing in cardiac surgery. *Semin Thromb Hemost* 2017;43(04):386–396
 - 33 Bickdeli B, Abou Ziki MD, Lip GYH. Pulmonary embolism and atrial fibrillation: two sides of the same coin? A systematic review. *Semin Thromb Hemost* 2017;43(08):849–863
 - 34 Mahajan A, Brunson A, White R, Wun T. The epidemiology of cancer-associated venous thromboembolism: an update. *Semin Thromb Hemost* 2019;45(04):321–325
 - 35 Van Cott EM, Roberts AJ, Dager WE. Laboratory monitoring of parenteral direct thrombin inhibitors. *Semin Thromb Hemost* 2017;43(03):270–276
 - 36 Davie EW, Kulman JD. An overview of the structure and function of thrombin. *Semin Thromb Hemost* 2006;32(Suppl 1):3–15
 - 37 Reynen E, James P. Von Willebrand disease and pregnancy: a review of evidence and expert opinion. *Semin Thromb Hemost* 2016;42(07):717–723
 - 38 McEwen BJ. The influence of herbal medicine on platelet function and coagulation: a narrative review. *Semin Thromb Hemost* 2015;41(03):300–314
 - 39 Thachil J. The elusive diagnosis of disseminated intravascular coagulation: does a diagnosis of DIC exist anymore? *Semin Thromb Hemost* 2019;45(01):100–107
 - 40 Lippi G, Plebani M, Favaloro EJ. Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. *Semin Thromb Hemost* 2013;39(03):258–266
 - 41 Arachchillage DRJ, Makris M. Inherited thrombophilia and pregnancy complications: should we test? *Semin Thromb Hemost* 2019;45(01):50–60
 - 42 Lippi G, Gosselin R, Favaloro EJ. Current and emerging direct oral anticoagulants: state-of-the-art. *Semin Thromb Hemost* 2019;45(05):490–501
 - 43 Molhoek JE, de Groot PG, Urbanus RT. The lupus anticoagulant paradox. *Semin Thromb Hemost* 2018;44(05):445–452
 - 44 Anker-Møller T, Troldborg A, Sunde N, Hvas AM. Evidence for the use of tranexamic acid in subarachnoid and subdural hemorrhage: a systematic review. *Semin Thromb Hemost* 2017;43(07):750–758
 - 45 Arachchillage DR, Laffan M. Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms. *Semin Thromb Hemost* 2019;45(06):604–611
 - 46 Grandone E, Ostuni A, Tiscia GL, Marongiu F, Barcellona D. Management of patients taking oral anticoagulants who need urgent surgery for hip fracture. *Semin Thromb Hemost* 2019;45(02):164–170
 - 47 International Council for Standardization in Haematology (ICSH). Accessed January 30, 2021 at: <https://icsh.org/>
 - 48 Favaloro EJ. 2020 Eberhard F. Mammen award announcements: part I—most popular articles. *Semin Thromb Hemost* 2020;46(04):383–392
 - 49 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)—part I. *Semin Thromb Hemost* 2020;46(07):757–762
 - 50 Hvas AM, Larsen JB, Pasalic L. Acquired platelet dysfunction—laboratory and clinical implications. *Semin Thromb Hemost* 2020;46(03):235–237
 - 51 Van Cott EM, Smock KJ, Lippi G. Innovations in thrombosis and hemostasis: a glimpse towards the future of diagnostic analyzers. *Semin Thromb Hemost* 2019;45(03):225–227
 - 52 Schulman S. Recent advances in thrombosis and hemostasis—part IV. *Semin Thromb Hemost* 2019;45(02):130–131
 - 53 Favaloro EJ, Lippi G. Editorial compilation VI. *Semin Thromb Hemost* 2019;45(01):5–9
 - 54 Adams MJ, Fell JW. Hemostasis in exercise and the athlete. *Semin Thromb Hemost* 2018;44(08):707–709
 - 55 Favaloro EJ, Lippi G. Editorial compilation V. *Semin Thromb Hemost* 2018;44(03):193–196
 - 56 Favaloro EJ, Lippi G. Editorial compilation VIII. *Semin Thromb Hemost* 2020;46(04):393–397
 - 57 Favaloro EJ, Lippi G. Editorial compilation VII. *Semin Thromb Hemost* 2019;45(05):429–432
 - 58 Kitchen S, Tiefenbacher S, Gosselin R. Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies. *Semin Thromb Hemost* 2017;43(03):331–337
 - 59 Favaloro EJ. 2019 Eberhard F. Mammen award announcements: part I—most popular articles. *Semin Thromb Hemost* 2019;45(03):215–224
 - 60 Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. *Semin Thromb Hemost* 1998;24(02):195–202
 - 61 Favaloro EJ. 2017 Eberhard F. Mammen award announcements: part II—young investigator awards. *Semin Thromb Hemost* 2018;44(02):81–88
 - 62 Favaloro EJ. A 2018 update on the editorial and publication policy of seminars in thrombosis and hemostasis. *Semin Thromb Hemost* 2018;44(04):307–311
 - 63 Russo V, Attenu E, Mazzone C, et al. Nonvitamin K antagonist oral anticoagulants use in patients with atrial fibrillation and bioprosthetic heart valves/prior surgical valve repair: a multicenter clinical practice experience. *Semin Thromb Hemost* 2018;44(04):364–369